source
- Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitisBoth Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
- Zero-tolerance signs in hospitals may not curb staff violence, authors argueHospitals across the United States now display signs telling patients and visitors that abusive language, disruptive conduct, or aggression will not be tolerated and may result in removal or police…